Evidence for the Endocannabinoid System as a Therapeutic Target in the Treatment of Cannabis Use Disorder
Authors:
- 9 November 2020
- journal article
- research article
- Published by Springer Nature in Current Addiction Reports
- Vol. 7 (4) , 545-552
Abstract
Purpose of Review Cannabis use disorder (CUD) is highly prevalent. Psychotherapeutic treatment alone is not adequately effective, with few individuals achieving abstinence. Pharmacotherapeutic supplementation may improve efficacy, and the endocannabinoid system presents a target specifically dysregulated by heavy cannabis use. This review compiles current literature evaluating endocannabinoid modulation as a treatment strategy for CUD, with implications for future research. Recent Findings Cannabinoid receptor agonists have been found to reduce cannabis withdrawal symptoms without a notable effect on relapse, and antagonists can produce severe psychiatric symptoms. Fatty acid amide hydrolase inhibitors and cannabidiol demonstrate the most promise in treating CUD thus far, but research with these compounds is still preliminary. Summary Components of the endocannabinoid system may serve as unique treatment targets with differential efficacy for the treatment of cannabis use disorder as a whole. Further research is needed exploring novel methods for targeting endocannabinoid dysfunction in CUD.Keywords
Funding Information
- National Institute on Drug Abuse (K24DA038240, T32DA007288)
This publication has 84 references indexed in Scilit:
- Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokersMolecular Psychiatry, 2011
- Dronabinol for the treatment of cannabis dependence: A randomized, double-blind, placebo-controlled trialDrug and Alcohol Dependence, 2011
- Separate and combined effects of the cannabinoid agonists nabilone and Δ9-THC in humans discriminating Δ9-THCDrug and Alcohol Dependence, 2011
- FAAH−/− Mice Display Differential Tolerance, Dependence, and Cannabinoid Receptor Adaptation After Δ9-Tetrahydrocannabinol and Anandamide AdministrationNeuropsychopharmacology, 2010
- Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stressPsychoneuroendocrinology, 2009
- Stress-related factors in cannabis use and misuse: Implications for prevention and treatmentJournal of Substance Abuse Treatment, 2009
- Fatty Acid Amide Hydrolase Inhibition Heightens Anandamide Signaling Without Producing Reinforcing Effects in PrimatesBiological Psychiatry, 2008
- Blockade of THC-Seeking Behavior and Relapse in Monkeys by the Cannabinoid CB1-Receptor Antagonist RimonabantNeuropsychopharmacology, 2008
- Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapsePsychopharmacology, 2007
- Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis usersPsychopharmacology, 2007